Trial Profile

A Phase 1, Open-Label, Food Effect, And Dose Proportionality Study With Omaveloxolone In Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omaveloxolone (Primary)
Indications Friedreich's ataxia; Malignant melanoma; Mitochondrial disorders; Non-small cell lung cancer; Ocular inflammation; Ocular pain
Focus Pharmacokinetics
Sponsors Reata Pharmaceuticals

Most Recent Events

26 Oct 2023 In September 2023, Reata Pharmaceuticals was acquired and merged into Biogen and study is completed in 2018 so not added biogen in association
27 Aug 2019 Status changed from recruiting to completed.
12 Nov 2018 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com